<DOC>
	<DOCNO>NCT01925989</DOCNO>
	<brief_summary>This two-period study participant type 1 diabetes mellitus ( T1DM ) . In period , participant receive daily injection stable dose LY2605541 insulin glargine 28 35 day follow procedure look body us store fat sugar . Participants continue use meal time insulin throughout study . Healthy participant also enroll study . They receive study medication .</brief_summary>
	<brief_title>A Study How LY2605541 Insulin Glargine Affect Breakdown Fat Sugar Type 1 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 Diabetics : T1DM 1 year Hemoglobin A1c ( HbA1c ) less 9.5 % All Participants : Otherwise fit healthy Non smoker Type 1 Diabetics : Taking medication supplement insulin control diabetes Suffered hypoglycemic event last 12 month require hospitalization poor awareness hypoglycemia All Participants : Taking fibrates , thyroid replacement therapy , testosterone , beta blocker systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>